title: Neoadjuvant therapy for localized pancreatic cancer: support is growing?
authors.affiliation: From the Pancreatic Cancer Program, Departments of Surgery, Medicine, and Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Douglas B
authors.initials: DB
authors.lastname: Evans
authors.forename: Paul S
authors.initials: PS
authors.lastname: Ritch
authors.forename: Beth A
authors.initials: BA
authors.lastname: Erickson
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage*; D008297:Male; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000628:therapy*
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin